Beyond Dense Deposit Disease: Complement-Mediated MPGN Carries a Higher Risk of Retinal Disease and Vision Loss

Study: Dalvin and colleagues compared ocular findings in two kidney-biopsy-defined forms of membranoproliferative glomerulonephritis (MPGN), using a retrospective Mayo Clinic series spanning ophthalmic records from 1997–2014. Among 46 patients with confirmed MPGN and available eye examinations, 23 had complement-mediated MPGN (C3 glomerulopathy) and 23 had immune complex-mediated MPGN. Retinal findings likely related to renal disease were documented in 9/23 (39%) complement-mediated patients (17/46 eyes, 37%), versus an initial 2/23 (9%) immune complex-mediated patients (4 eyes); detailed review considered one of the latter cases likely unrelated, leaving just 1/23 (4%) with possibly related drusen. Severe visual impairment (20/200 or worse) affected 5/23 (22%) complement-mediated patients (6/46 eyes, 13%) and none of the immune complex-mediated group. These selected retrospective observations support baseline dilated eye examinations and continued surveillance in complement-mediated MPGN, but do not establish population incidence or an optimal screening interval.

Historically MPGN was divided into types I, II (dense deposit disease, DDD), and III by electron microscopy. The contemporary pathogenesis-based distinction uses renal immunofluorescence: complement-mediated MPGN (including DDD and C3 glomerulonephritis, C3GN) versus immune complex-mediated MPGN. Older types I and III do not map reliably onto either new group. Restricting retinal screening attention to former type II/DDD would therefore miss patients with complement-mediated disease and drusen-like deposits.

Design: retrospective consecutive clinical-record review at Mayo Clinic Rochester, not a prospective screened population cohort. The initial electronic search identified 662 possible MPGN records; 73 had documented dilated ophthalmic examinations, and 27 of those were excluded after pathology review, leaving 46 biopsy-confirmed patients: 23 in each pathogenesis-defined group. The review examined available clinical ophthalmic records and, where present, fundus photographs, OCT and fluorescein angiography. There was no uniform imaging protocol or predefined longitudinal visit schedule.

The mean age at first documented eye examination was 41 ± 21 years in the complement-mediated group and 46 ± 19 years in the immune complex-mediated group (P = .40). Mean available follow-up after renal diagnosis was approximately 8 ± 5 and 9 ± 5 years, respectively (P = .63). The investigators primarily described retinal findings and vision, not formal diagnostic sensitivity or time-to-event risks.

Of 23 patients (46 eyes), 9 patients (39%) and 17 eyes (37%) had retinal abnormalities judged likely related to complement-mediated disease. Findings comprised drusen in 6 patients/12 eyes, nonspecific pigment changes in 1 patient/2 eyes, bone-spicule-like pigment changes in 1 patient/2 eyes, and retinal detachment with pigment changes in 1 patient/1 eye. Ten patients had no ocular abnormalities and four had findings considered unrelated (including retinal vein occlusion, diabetic retinopathy, pigment dispersion syndrome or multifocal choroiditis).

Five patients (22% of all 23) and six eyes (13% of 46) had most-recent BCVA of 20/200 or worse. An additional patient had visual-field deficits despite 20/20 acuity. Retinal findings were present on the first available examination in affected patients, sometimes at very young ages: the youngest patient with findings was 18. Mean time between renal diagnosis and first recognition of retinal findings was reported as 6 ± 3 years, ranging from concurrent recognition to nine years afterward; this should not be interpreted as a prospectively measured onset interval.

Two of 23 patients (9%; four eyes) initially had drusen-like abnormalities that could have appeared related. On image/chart review, one patient had probable steroid-associated choroidal changes consistent with mild central serous chorioretinopathy, considered unrelated to MPGN. Thus only one patient (4%; two eyes) remained as a possible MPGN-related drusen case, without available photographs to verify the attribution. No patient in this group experienced vision loss attributed to the renal-associated retinal process. The paper reported fewer potentially affected eyes than in the complement-mediated group (P = .001) after this adjudication.

Do not conflate the abstract’s broader 2/23 (9%) figure with the discussion’s stricter 1/23 (4%) figure; both describe different levels of attribution.

The authors propose a shared vulnerability of the glomerular filtration interface and the choriocapillaris–Bruch’s membrane–RPE complex, both relatively dependent on soluble complement regulation. Complement factor H (CFH) normally restrains alternative-pathway C3 amplification. Dysregulation may contribute to glomerular deposits and sub-RPE drusen-like material, paralleling complement biology implicated in age-related macular degeneration (AMD).

Genetic testing was available in only three complement-mediated patients with retinal findings; all carried CFH-associated risk alleles, and one also had C3-associated alleles. This supports biological plausibility but does not demonstrate that these alleles predict ocular disease in the broader MPGN population or prove causation in individual patients.

Clinical examination may reveal macular or extramacular drusen-like deposits, RPE mottling, pigment migration, atrophy, subretinal fibrosis, subretinal fluid or other retinal changes. OCT can document sub-RPE deposits, outer-retinal changes and exudation; fluorescein angiography can be considered if leakage or choroidal neovascularization (CNV) is suspected. The authors recommend multimodal evaluation for patients with clinically evident lesions, rather than relying on ophthalmoscopy alone.

Important differential diagnoses include age-related drusen/AMD, pachychoroid or steroid-associated central serous chorioretinopathy, inherited drusen disorders, diabetic retinal disease and unrelated vascular or inflammatory abnormalities. A drusen-like appearance is not by itself proof of a complement-mediated renal mechanism.

One severely affected patient with subretinal fluid improved from 20/400 to 20/200 in each eye after monthly aflibercept injections, consistent with the potential role of anti-VEGF treatment for active neovascular complications. However, this is a single clinical observation, not evidence for prophylactic anti-VEGF or a general treatment effect in MPGN-associated drusen.

Two patients with retinal findings received systemic eculizumab, with markedly different ocular outcomes; the authors could not establish whether complement inhibition prevents or treats retinal pathology. Renal transplant requirements and immunosuppressive treatment were not clearly associated with retinal involvement in this small cohort. Systemic treatment decisions remain the nephrology team’s responsibility.

Complement-mediated MPGN: Arrange a baseline dilated retinal examination at diagnosis, with careful attention to drusen-like deposits and pigmentary changes, even in young adults. Consider color fundus photography and OCT to document baseline morphology; use additional angiographic imaging when exudation is suspected. Repeat examinations according to findings and clinical judgment; this study did not establish an evidence-based surveillance interval.

Immune complex-mediated MPGN: The observed ocular burden was much lower, but the authors still advise careful ophthalmic evaluation of patients with MPGN while larger studies are pending. Counsel patients with new distortion, scotoma or vision decline to seek prompt assessment.

• Major selection bias: only 73 of 662 initially identified records had documented dilated examinations; after pathology exclusions only 46 were analyzed. The observed proportions are not prevalence estimates for all patients with MPGN.
• Small samples: 23 patients per etiologic group and very few severe events; proportions are unstable and subgroup analyses underpowered.
• Retrospective attribution: eye findings were categorized as likely, possibly, or unrelated based on existing records, with incomplete photographs/OCT and no standardized masked grading.
• Confounding: age, renal disease course, systemic therapy, ocular comorbidities and examination patterns may affect observed differences. Similar transplant rates do not eliminate these biases.
• No prospective timing: retinal abnormalities were already present at the first documented eye examination, precluding reliable estimation of incidence, onset or progression.
• Genetic data limited: CFH/C3 variants were available in only three affected complement-mediated patients; no genetic comparisons were possible.
• Reporting nuance: the abstract reports 2 immune complex-mediated patients with potentially related findings, whereas detailed review rejects one as probable steroid-related CSC, leaving one possible case.
• Historical context: published in 2016; this study alone does not establish contemporary best practices or efficacy of newer complement-directed interventions.

Renal immunofluorescence classification is clinically relevant to the retina: in this selected Mayo Clinic series, complement-mediated MPGN was associated with more frequent drusen-like and pigmentary retinal abnormalities and clinically important visual loss, while immune complex-mediated MPGN showed few plausibly related ocular findings. The evidence supports early retinal assessment and ongoing individualized surveillance for complement-mediated disease, without implying a validated screening interval, a causal genetic prediction model or proven ocular benefit from systemic complement inhibition.